OBJECTIVE: To evaluate the safety and efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in patients with advanced penile or scrotal cancer. PATIENTS AND METHODS: We retrospectively reviewed the charts of patients with penile or scrotal squamous cell carcinoma who had visited our tertiary cancer centre between 2002 and 2009, including their subsequent treatment and follow-up. We collected details of EGFR-targeted therapy and clinical outcomes. Treatment-associated time-to-disease-progression (TTP), overall survival (OS), responses to therapy and toxicity were evaluated. RESULTS: A total of 24 patients had received EGFR-targeted therapies, including cetuximab, erlotinib and gefitinib. The most common treatment given (to 67% of patients) was cetuximab combined with one or more cytotoxic drugs. The most common adverse effect was skin rash (71%). The median (range) TTP and OS were 11.3 (1-40) and 29.6 (2-205) weeks, respectively. The OS time for patients with visceral or bone metastases was significantly shorter than it was for those without (24.7 vs 49.9 weeks, P = 0.013). Among 17 patients treated with cetuximab alone or in combination with cisplatin, there were four partial responses (23.5%) including two patients with apparently chemotherapy-resistant tumours. CONCLUSIONS: Our results suggest that cetuximab has antitumour activity in metastatic penile cancer, and may enhance the effect of cisplatin-based chemotherapy. Prospective studies of EGFR-targeted therapies in men with these tumours are warranted.
OBJECTIVE: To evaluate the safety and efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in patients with advanced penile or scrotal cancer. PATIENTS AND METHODS: We retrospectively reviewed the charts of patients with penile or scrotal squamous cell carcinoma who had visited our tertiary cancer centre between 2002 and 2009, including their subsequent treatment and follow-up. We collected details of EGFR-targeted therapy and clinical outcomes. Treatment-associated time-to-disease-progression (TTP), overall survival (OS), responses to therapy and toxicity were evaluated. RESULTS: A total of 24 patients had received EGFR-targeted therapies, including cetuximab, erlotinib and gefitinib. The most common treatment given (to 67% of patients) was cetuximab combined with one or more cytotoxic drugs. The most common adverse effect was skin rash (71%). The median (range) TTP and OS were 11.3 (1-40) and 29.6 (2-205) weeks, respectively. The OS time for patients with visceral or bone metastases was significantly shorter than it was for those without (24.7 vs 49.9 weeks, P = 0.013). Among 17 patients treated with cetuximab alone or in combination with cisplatin, there were four partial responses (23.5%) including two patients with apparently chemotherapy-resistant tumours. CONCLUSIONS: Our results suggest that cetuximab has antitumour activity in metastatic penile cancer, and may enhance the effect of cisplatin-based chemotherapy. Prospective studies of EGFR-targeted therapies in men with these tumours are warranted.
Authors: G P Haas; B A Blumenstein; R G Gagliano; C A Russell; S E Rivkin; D J Culkin; M Wolf; E D Crawford Journal: J Urol Date: 1999-06 Impact factor: 7.450
Authors: Carlos Bermejo; J Erik Busby; Philippe E Spiess; Lior Heller; Lance C Pagliaro; Curtis A Pettaway Journal: J Urol Date: 2007-04 Impact factor: 7.450
Authors: C Theodore; I Skoneczna; I Bodrogi; M Leahy; J M Kerst; L Collette; K Ven; S Marréaud; R D T Oliver Journal: Ann Oncol Date: 2008-04-15 Impact factor: 32.976
Authors: Giuseppe Di Lorenzo; Carlo Buonerba; Gabriella Gaudioso; Vincenzo Gigantino; Giuseppe Quarto; Renato De Domenico; Michele Caraglia; Rossella Di Trolio; Paolo A Ascierto; Sabino De Placido; Sisto Perdonà; Renato Franco Journal: Expert Opin Ther Targets Date: 2013-03-22 Impact factor: 6.902
Authors: James M Cleary; David A Reardon; Nilofer Azad; Leena Gandhi; Geoffrey I Shapiro; Jorge Chaves; Michelle Pedersen; Peter Ansell; William Ames; Hao Xiong; Wijith Munasinghe; Matt Dudley; Edward B Reilly; Kyle Holen; Rod Humerickhouse Journal: Invest New Drugs Date: 2015-04-17 Impact factor: 3.850
Authors: Siraj M Ali; Sumanta K Pal; Kai Wang; Norma A Palma; Eric Sanford; Mark Bailey; Jie He; Julia A Elvin; Juliann Chmielecki; Rachel Squillace; Edward Dow; Deborah Morosini; Jamie Buell; Roman Yelensky; Doron Lipson; Garrett M Frampton; Peter Howley; Jeffrey S Ross; Philip J Stephens; Vincent A Miller Journal: Oncologist Date: 2015-12-15
Authors: Ahmet Murat Aydin; Jad Chahoud; Jacob J Adashek; Mounsif Azizi; Anthony Magliocco; Jeffrey S Ross; Andrea Necchi; Philippe E Spiess Journal: Nat Rev Urol Date: 2020-08-18 Impact factor: 14.432